Latest news with #Heaton
Yahoo
2 days ago
- Business
- Yahoo
Owner of Utah outdoor retailer sentenced for tax fraud, ordered to pay over $2M
SALT LAKE CITY () — The owner of a Utah-based outdoor retailer was sentenced to five months imprisonment after he evaded paying taxes for six years. In February, Phyllip Hallman Heaton, 43, of Washington City, the owner of Zion Outfitter, pleaded guilty to charges related to tax evasion. In addition to the prison sentence, Heaton was also sentenced to 18 months of supervised release, including six months of home detention. The court also ordered Heaton to pay a $95,000 fine and $1,947,906 in restitution, which the Department of Justice said he paid in full at his sentencing. According to court documents, Heaton evaded taxes by underreporting his income to the IRS by more than $5.4 million between 2017 and 2022. The Department of Justice said Heaton's actions resulted in him evading nearly $2 million in taxes. Suspect hides in trap door during SWAT raid in Murray 'No one can decide they are not going to pay their fair share of taxes without serious consequences,' said Acting U.S. Attorney Felice John Viti of the District of Utah. 'Mr. Heaton's sentence is one such consequence and also serves as a deterrence to others by demonstrating that tax evasion comes with serious penalties from the Department of Justice.' Zion Outfitter, a southern Utah rental company, is situated near the pedestrian entrance of Zion National Park. The business provides rentals for bikes, tubes, and gear for canyoneering. According to the website, Zion Outfitters' doors are still open and the company is operating as usual. ABC4 has reached out to Zion Outfitter and will update this story with any new information. A Utah woman's passion for kindness transforms lives in Downtown Salt Lake Latter-day Saint honored with Polar Star Medal in Mongolia Owner of Utah outdoor retailer sentenced for tax fraud, ordered to pay over $2M 24-year-old pleads guilty to chasing down, killing 17-year-old victim in Cedar City Comer demands interviews with former top Biden aides as part of probe into mental acuity Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Scottish Sun
7 days ago
- Sport
- Scottish Sun
Man Utd ratings: Chido Obi immediately outshines woeful Hojlund while Heaton must hope contract offer is still on table
CHIDO-OBI spared Manchester United's blushes after his brace completed a 3-1 comeback win against Hong Kong. But Tom Heaton's disastrous clanger almost caused back-to-back postseason defeats in Asia, with United losing to ASEAN All-Stars on Wednesday. Advertisement 6 Chido Obi's brace saved Ruben Amorim's skin in Hong Kong Credit: Getty 6 Man Utd went 1-0 down inside 20 minutes Credit: Reuters The Red Devils dominated the early exchanges, before Heaton's shocking howler saw United 1-0 down against the run of play. Brazilian-born Juninho was played in behind, before his low shot somehow wriggled under Heaton at the front post. The goal took the wind out of United's sails, as they carried on the trend of their heads going down after conceding early. Amorim had seen enough and changed the entire XI at half-time before Obi's first senior goal levelled the scores within four minutes. Advertisement The sensational teen saved Amorim's skin after doubling the lead in the last ten minutes, before Ayden Heaven's header made it 3-1. Hong Kong, who are just above Moldova in the Fifa world rankings, scored from ONE shot at goal - United failed to do so in 15 first-half attempts. For now fans can be thankful that United won't be back in action until pre-season. Hopefully they shift the deadwood by then. Here's how SunSport's Katherine Walsh rated the Man Utd performances against Hong Kong -who are ranked 153 in the world. Advertisement Tom Heaton - 0 The veteran goalkeeper, 39, proved why he shouldn't be given a one-year extension this summer- even if it's in a coaching capacity. His blunder came with his first touch of the ball, when Juninho's limp shot - straight at him - bounced into the net. Heaton was expected leave as a free agent and possibly even hang up his gloves when his £45,000-a-week contract expires this summer. And he should go, even if it was his final game. Awful. Advertisement Tyler Fredricson - 4 Unfortunate not have equalised when he slipped through defenders to guide a header down straight into the Hong Kong goalkeeper. Got his positioning run for Hong Kong's opener. 6 Tyler Fredricson was unfortunate not have equalised before Obi did Credit: Getty Jonny Evans - 4 What a sorry way to end your footballing career. Evans won't play for United again. Advertisement And the Northern Irishman didn't have a lot to do here. It feels harsh because the 37-year-old has been a brilliant professional. Godwill Kukonki - 5 The 17-year-old from Stoke-on-Trent didn't get close enough to block or put off goalscorer Juninho. He wasn't asked to do much else. Was always the first of the back line of defenders to react to any loose ball in United's own final third. Jaydan Kamason - 5 Was awarded his first start after a decent 20 minute cameo the defeat to ASEAN All-Stars on Wednesday. Advertisement The right-back, 18, showed Diogo Dalot how to cross a good ball. Was unlucky to have his late arriving shot cleared off the line in the 37th minute. Harry Amass - 5 Didn't feature in the defeat in Malaysia, but started brightly here. Before a few wayward crosses left Amorim grimacing. Advertisement Bruno Fernandes - 6 The man of the moment perhaps took the armband for the final time with £100million links to Saudi Arabian side Al-Hilal ramping up. He's the player fans in Hong Kong came to see, sending a delicious free-kick into his midfield pal early on. The Portugal star showboated to treat the crowd when his cheeky rabona shot was kept out by the keeper. Tested the goalkeeper with a free-kick on the slippery surface again, before it was parried out for a corner. Linked up well with Garnacho. Advertisement But for a player who has worked so hard all season, you've got to feel sorry for him playing 6,000 miles away a few days after the final day. 6 Bruno Fernandes could've worn the Man Utd armband for the final time Casemiro - 4 The 33-year-old just wants to be on his holidays after a topsy-turvy individual season. He played his way back into United's good-books since the Lyon comeback, but was out-paced by a fast teenager in the opening seconds. Advertisement The recently recalled Brazilian international had a gliding header ruled out in the fourth minute from Fernandes' set piece. Brilliant bit of skill for an Amass chance before 1-0. Alejandro Garnacho - 5 Could've been Garnacho's last game for the club too. Perhaps it shouldn't be because he was the brightest spark here. The 20-year-old rowing with Amorim threatened to be up to usual tricks, or lack thereof, failing to beat his man in the opening minute. Advertisement But the Chelsea target soon settled and flashed several inviting balls across the box and was involved in all of the action. Shea Lacey - 6 The 18-year-old winger from Liverpool did well to win the free-kick Casemiro scored from early on, and he won another a few minutes later. But he scuffed a certain goal wide of the post from Garnacho's cross in the 15th minute. Silky footwork and a willingness to get forward, Lacey looks like he could be a bright spark for the future at Old Trafford. Advertisement Was hooked for Tyler Fletcher on the half-an-hour-mark. 6 Shea Lacey won two inviting free-kicks in his short cameo Credit: Getty Rasmus Hojlund - 1 Fluffed half a chance in the opening minutes and was anonymous. When finally called upon, the Dane failed to control Fernandes' blocked rabona, before Kamason's shot was cleared off the line. Advertisement FIRST-HALF SUBS Tyler Fletcher - (for Lacey '27) - 5 Man United legend Darren Fletcher's son couldn't get hold of the ball much. Sekou Kone (for Casemiro '27) - 5 Powered forward and has go at goal from outside the box but it flies wide of the post. Joined Fletcher in lasting 15 minutes before being part of the half-time changes. HALF-TIME SUBS Chido Obi - 8 His first goal for Amorim was a tidy finish in the 49th minute. Advertisement The teenager took two touches with the ball to his right and lashed a shot into the back of the net on his weak foot. Obi completed the comeback with a direct header into the corner in the 82nd minute. 6 Chido Obi-Martin completed the turn around Credit: Getty Altay Bayindir - 6 Didn't have to much before his low save kept the home side out in the 68th minute. Advertisement Ayden Heaven - In the second-half, Heaven became the most experienced centre-back on the pitch for United - he's 18. The former Arsenal man was confident enough to step into that role and looks like a talent for the future. He joined Obi in getting on the scoresheet for the first time, with a well-placed header in the final minute of added time. Dan Armer - 5 Scotland Under-19 international centre-back picked up valuable experience again. Advertisement Jim Thwaites, who saved United from losing 2-0 on Wednesday, replaced Armer inside 72 minutes. Amad Diallo - 6 Amad knows he's been one of the few bright sparks for United this season and he played like it too. It wasn't his usual display of blistering pace and hard work, but rather a tame effort to help the team while avoiding injury. Toby Collyer - 5 Collyer has been one of the Carrington stars that has been in and around the first team for a while, and it's obvious why. Advertisement He looks like he's ready to make a more regular step up to first team football and could be a part of the squad rotations next season. Made way for Jack Moorhouse in the 73rd minute. Manuel Ugarte - 4 Ugarte poked the ball to Obi in the penalty area for the equaliser. Was a big part of United winning the ball back high up in the second half. But so he should be, he was the most experienced on the pitch. Advertisement Patrick Dorgu - 5 Unlucky not to have won a penalty in the opening seconds of the second-half. Mason Mount - 6 Denied the chance to put United 2-1 up when the keeper brilliantly saved in the 55th minute. Great delivery from a free-kick which blasted past the goal-line in the 66th minute. Bagged a brilliant assist with a floating ball for Obi's second. Kobbie Mainoo - 4 Mainoo was United's starboy and England's best holding midfielder at the Euros. Advertisement He'll be annoyed not to get minutes in his favoured position, instead struggling as one of the two No 10s in Amorim's 3-4-3. Mainoo looks shot for confidence and fluffed a chance in the 75th minute. Fans will be worried about the Manchester-born ace leaving this summer.
The Irish Sun
7 days ago
- Sport
- The Irish Sun
Man Utd ratings: Chido Obi immediately outshines woeful Hojlund while Heaton must hope contract offer is still on table
CHIDO-OBI spared Manchester United's blushes after his brace completed a 3-1 comeback win against Hong Kong. But Advertisement 6 Chido Obi's brace saved Ruben Amorim's skin in Hong Kong Credit: Getty 6 Man Utd went 1-0 down inside 20 minutes Credit: Reuters The Red Devils dominated the early exchanges, before Heaton's shocking howler saw United 1-0 down against the run of play. Brazilian-born Juninho was played in behind, before his low shot somehow wriggled under Heaton at the front post. The goal took the wind out of United's sails, as they carried on the trend of their heads going down after conceding early. Amorim had seen enough and changed the entire XI at half-time before Advertisement The sensational teen saved Amorim's skin after doubling the lead in the last ten minutes, before Hong Kong, who are just above Moldova in the Fifa world rankings, scored from ONE shot at goal - United failed to do so in 15 first-half attempts. For now fans can be thankful that United won't be back in action until pre-season. Hopefully they shift the deadwood by then. Here's how SunSport's Katherine Walsh rated the Man Utd performances against Hong Kong -who are ranked 153 in the world. Advertisement Most read in Football Tom Heaton - 0 The veteran goalkeeper, 39, proved why he shouldn't be given a one-year extension this summer - even if it's in a coaching capacity. His blunder came with his first touch of the ball, when Juninho's limp shot - straight at him - bounced into the net. Heaton was expected leave as a free agent and possibly even hang up his gloves when his £45,000-a-week contract expires this summer . And he should go, even if it was his final game. Awful. Advertisement Tyler Fredricson - 4 Unfortunate not have equalised when he slipped through defenders to guide a header down straight into the Hong Kong goalkeeper. Got his positioning run for Hong Kong's opener. 6 Tyler Fredricson was unfortunate not have equalised before Obi did Credit: Getty Jonny Evans - 4 What a sorry way to end your footballing career. Evans won't play for United again. Advertisement And the Northern Irishman didn't have a lot to do here. It feels harsh because the 37-year-old has been a brilliant professional. Godwill Kukonki - 5 The 17-year-old from Stoke-on-Trent didn't get close enough to block or put off goalscorer Juninho. He wasn't asked to do much else. Was always the first of the back line of defenders to react to any loose ball in United's own final third. Jaydan Kamason - 5 Was awarded his first start after a decent 20 minute cameo the defeat to ASEAN All-Stars on Wednesday. Advertisement The right-back, 18, showed Diogo Dalot how to cross a good ball. Was unlucky to have his late arriving shot cleared off the line in the 37th minute. Harry Amass - 5 Didn't feature in the defeat in Malaysia, but started brightly here. Before a few wayward crosses left Amorim grimacing. Advertisement Bruno Fernandes - 6 The man of the moment perhaps took the armband for the final time with He's the player fans in Hong Kong came to see, sending a delicious free-kick into his midfield pal early on. The Tested the goalkeeper with a free-kick on the slippery surface again, before it was parried out for a corner. Linked up well with Garnacho. Advertisement But for a player who has worked so hard all season, you've got to feel sorry for him playing 6,000 miles away a few days after the final day. 6 Bruno Fernandes could've worn the Man Utd armband for the final time Casemiro - 4 The 33-year-old just wants to be on his holidays after a topsy-turvy individual season. He played his way back into United's good-books since the Advertisement The recently recalled Brazilian international had a gliding header ruled out in the fourth minute from Fernandes' set piece. Brilliant bit of skill for an Amass chance before 1-0. Alejandro Garnacho - 5 Could've been Garnacho's last game for the club too. Perhaps it shouldn't be because he was the brightest spark here. The Advertisement But the target soon settled and flashed several inviting balls across the box and was involved in all of the action. Shea Lacey - 6 The 18-year-old winger from Liverpool did well to win the free-kick But he scuffed a certain goal wide of the post from Garnacho's cross in the 15th minute. Silky footwork and a willingness to get forward, Lacey looks like he could be a bright spark for the future at Old Trafford. Advertisement Was hooked for Tyler Fletcher on the half-an-hour-mark. 6 Shea Lacey won two inviting free-kicks in his short cameo Credit: Getty Rasmus Hojlund - 1 Fluffed half a chance in the opening minutes and was anonymous. When finally called upon, the Dane failed to control Fernandes' blocked rabona, before Kamason's shot was cleared off the line. Advertisement FIRST-HALF SUBS Tyler Fletcher - (for Lacey '27) - 5 Man United legend Darren Fletcher's son couldn't get hold of the ball much. Sekou Kone (for Casemiro '27) - 5 Powered forward and has go at goal from outside the box but it flies wide of the post. Joined Fletcher in lasting 15 minutes before being part of the half-time changes. HALF-TIME SUBS Chido Obi - 8 His first goal for Amorim was a tidy finish in the 49th minute. Advertisement The teenager took two touches with the ball to his right and lashed a shot into the back of the net on his weak foot. Obi completed the comeback with a direct header into the corner in the 82nd minute. 6 Chido Obi-Martin completed the turn around Credit: Getty Altay Bayindir - 6 Didn't have to much before his low save kept the home side out in the 68th minute. Advertisement Ayden Heaven - In the second-half, Heaven became the most experienced centre-back on the pitch for United - he's 18. The former man was confident enough to step into that role and looks like a talent for the future. He joined Obi in getting on the scoresheet for the first time, with a well-placed header in the final minute of added time. Dan Armer - 5 Scotland Under-19 international centre-back picked up valuable experience again. Advertisement Jim Thwaites, who saved United from losing 2-0 on Wednesday, replaced Armer inside 72 minutes. Amad Diallo - 6 Amad knows he's been one of the few bright sparks for United this season and he played like it too. It wasn't his usual display of blistering pace and hard work, but rather a tame effort to help the team while avoiding injury. Toby Collyer - 5 Collyer has been one of the Carrington stars that has been in and around the first team for a while, and it's obvious why. Advertisement He looks like he's ready to make a more regular step up to first team football and could be a part of the squad rotations next season. Made way for Jack Moorhouse in the 73rd minute. Manuel Ugarte - 4 Ugarte poked the ball to Obi in the penalty area for the equaliser. Was a big part of United winning the ball back high up in the second half. But so he should be, he was the most experienced on the pitch. Advertisement Patrick Dorgu - 5 Unlucky not to have won a penalty in the opening seconds of the second-half. Mason Mount - 6 Denied the chance to put United 2-1 up when the keeper brilliantly saved in the 55th minute. Great delivery from a free-kick which blasted past the goal-line in the 66th minute. Bagged a brilliant assist with a floating ball for Obi's second. Kobbie Mainoo - 4 Mainoo was United's starboy and England's best holding midfielder at the Euros. Advertisement He'll be annoyed not to get minutes in his favoured position, instead struggling as one of the two No 10s in Amorim's 3-4-3. Read more on the Irish Sun Mainoo looks shot for confidence and fluffed a chance in the 75th minute. Fans will be worried about the Manchester-born ace leaving this summer.
Glasgow Times
27-05-2025
- Entertainment
- Glasgow Times
Scots star who collaborated with Paul Heaton coming to Glasgow
Rianne Downey has been trending on Glasgow's music scene for the last few years after releasing tunes like Songbird and Home and Hard. READ NEXT: Manchester group who supported rock giants to perform in Glasgow Having performed with Heaton of The Beautiful South at TRNSMT in 2023, the singer has also opened up for The Courteeners and has sold out shows across the UK. On Saturday, December 6, the singer will be performing at the Old Fruitmarket in the city centre. The news comes after the release of Downey's new single, The Consequence Of Love, which came out this week. READ NEXT: American star to perform at iconic Barrowland Ballroom in Glasgow To purchase tickets for the Glasgow show, click HERE Tickets will go on sale at 10am on May 30.
Yahoo
15-05-2025
- Business
- Yahoo
Zomedica Announces First Quarter 2025 Financial Results: Revenue of $6.5 Million; 68% Gross Margin, and $65 Million in Liquidity to Support Growth
ANN ARBOR, MI / / May 15, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the first quarter ended March 31, 2025. "We are pleased with our performance in the first quarter as we posted record year over year revenue for the 17th straight quarter," said Larry Heaton, President and Chief Executive Officer of Zomedica. "Bolstered by continued and robust usage of our consumable PulseVet® products, and the continued growth and adoption of our TRUFORMA® products, we were able to deliver the strongest first quarter in company history. "Through further expansion of our portfolio, highlighted by the introduction of our new VETIGEL® product line, and the continued optimization of our commercial organization, we are seeing the positive impact in both placements and consumable usage, further supporting a foundation for recurring sales revenue in the future. "International sales continue to grow, with sales up 32% compared to the first quarter of 2024, driven by a combination of organic growth and orders from new distributor partners. Gross margin, a key component of reaching profitability, came in at 68% compared to 66% in the first quarter of 2024. "Based on the momentum we have created through the first quarter of the year, supported by the strength of our balance sheet, we believe that we are well positioned to aggressively execute on our strategy to drive the accelerated adoption of our innovative portfolio on a global scale," concluded Mr. Heaton. 2025 First Quarter Financial Highlights Revenue for the first quarter of 2025 grew by 4% to $6.5 million, compared to first quarter 2024 revenue, highlighted by 13% growth in the sale of Consumables, driven primarily by accelerating adoption of our TRUFORMA line of products and the continued, strong performance of PulseVet® trodes, from both new device installations and reorders associated with existing systems. Revenue by Product Segment: Therapeutic Device segment revenue, comprised of our PulseVet and Assisi® products, was $5.9 million, up 8% from first quarter 2024 revenues. Diagnostics segment revenue, comprised of our TRUFORMA®, TRUVIEW®, and VETGuardian® products, was $0.6 million, down 25% over first quarter 2024 revenues, primarily driven by large, initial distribution orders of VetGuardian products upon launching in the first quarter of last year, which did not repeat this year. Revenue by Product Category: Consumable revenues grew to $4.5 million, up 13% over first quarter 2024 revenues. Capital revenues were $2.0 million, down 12% from first quarter 2024 revenues, primarily impacted by the initial distribution orders for VETGuardian products placed last year as mentioned above. Gross margin was 68% for the first quarter of 2025. *Reported financial metrics, including year-over-year and sequential percentage changes, are calculated using actual results, which may not match calculations done using the figures shown in this press release due to rounding. Please refer to the Company's Form 10-Q for additional detail. 2025 First Quarter Results Review Revenue for the three months ended March 31, 2025, was $6.5 million, compared to $6.3 million for the three months ended March 31, 2024, an increase of $0.2 million or 4%. Highlighting the strong performance in the quarter was Therapeutics revenue growth of 8%, and Consumables revenue growth of 13% over the prior year quarter. Cost of revenue was $2.1 million, flat to cost of revenue for the three months ended March 31, 2024 on higher sales. Margins remained strong at 68%. Operating expenses for the first quarter of 2025 include a non-cash impairment charge of $55.8 million, triggered by the decline in the Company's market capitalization, a function of the Company's share price. Total operating expenses including this non-cash impairment charge were $69.0 million. Excluding the impairment charge, adjusted operating expenses were $13.2 million, $1.3 million or 9%, lower than the first quarter of 2024. Research and development expenses were $1.9 million, compared to $1.8 million for the three months ended March 31, 2024, an increase of $0.1 million or 5%, with costs related to the continued buildup of internal capabilities to develop, test, and manufacture our next generation of therapeutic and diagnostic products. Selling and marketing expenses were $5.0 million, compared to $4.1 million for the three months ended March 31, 2024, an increase of $0.9 million or 22%, primarily driven by the increased headcount of our sales department as we continued to build out our staff through recent hiring campaigns. General and administrative expenses were $6.3 million, compared to $8.6 million for the three months ended March 31, 2024, a decrease of $2.3 million or 27%, primarily driven by the non-recurrence of professional fees for specialized accounting and development work associated with acquisitions, the non-recurrence of one-time special meeting and proxy fees, and lower stock-based compensation expense. Net loss for the three months ended March 31, 2025, includes a non-cash impairment expense of $55.8M, triggered by the decline in the Company's market capitalization, as discussed above, producing an overall net loss of $63.8 million compared to a net loss of $9.2 million for the three months ended March 31, 2024. *Non-GAAP EBITDA loss (which includes adjustments for stock compensation) for the three months ended March 31, 2025, was $61.7 million compared to a loss of $7.5 million for the three months ended March 31, 2024, which again included the impairment expense of $55.8M triggered by the decline in the Company's market capitalization. When adjusting for the non-recurring items noted above and other non-cash items, **Adjusted Non-GAAP EBITDA loss was $5.7 million, compared to **Adjusted Non-GAAP EBITDA loss of $5.3 million for the first quarter of 2024. Liquidity and Outstanding Share Capital Zomedica had cash, cash equivalents, and available-for-sale securities of $64.6 million as of March 31, 2025, compared to $71.4 million as of December 31, 2024, in line with the Company's expectations. As of March 31, 2025, Zomedica had 979,949,668 common shares issued and outstanding. For complete financial results, please see Zomedica's filings on EDGAR and SEDAR+ or visit the Zomedica website at For percentage calculations please refer to the financial statements filed with the SEC on Thursday, May 15, 2025, along with other public filings. Conference Call Details Zomedica will host a conference call on Thursday, May 15, 2025, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its first quarter ended March 31, 2025. A question-and-answer session will follow management's prepared remarks. Event: Zomedica Corp. Q1 2025 Financial Results Conference CallDate: Thursday, May 15, 2025Time: 4:30 p.m. Eastern TimeLive Call: +1-800-717-1738 (U.S. Toll-Free) or +1-646-307-1865 (International)Webcast: LINK For interested individuals unable to join the conference call, a dial-in replay of the call will be available until Thursday, May 29, 2025, at 11:59 PM ET and can be accessed by dialing +1-844-512-2921 (U.S. Toll-Free) or +1-412-317-6671 (International) and entering replay pin number: 1148151. About Zomedica Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices, along with the TRUFORMA® diagnostic platform, TRUVIEW® digital cytology system, VETGuardian® no-touch monitoring system, and VETIGEL® hemostatic gel, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 8% in 2024 to $27 million and maintains a strong balance sheet with approximately $65 million in liquidity as of March 31, 2025. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit Follow Zomedica Email Alerts: LinkedIn: Facebook: X (formerly Twitter): Instagram: Cautionary Note Regarding Forward-Looking Statements Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information. Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts. Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies; the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments; uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at Readers are cautioned that this list of risk factors should not be construed as exhaustive. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information. Investor Relations Contact: Zomedica Investor Relationsinvestors@ Non-GAAP Measures Non-GAAP EBITDA, Adjusted Non-GAAP EBITDA, and other measures presented on an adjusted basis are not recognized terms under U.S. GAAP and do not purport to be alternatives to the most comparable U.S. GAAP amounts. Since all companies do not use identical calculations, our definition and presentation of these measures may not be comparable to similarly titled measures reported by other companies. Management uses the identified non-GAAP measures to evaluate the operating performance of the Company and its business segments and to forecast future periods. Management believes these non-GAAP measures assist investors and other interested parties in evaluating Zomedica's on-going operations and provide important supplemental information to management and investors regarding financial and business trends relating to Zomedica's financial condition and results of operations. Investors should not consider these non-GAAP measures as alternatives to the related GAAP measures. Reconciliations of non-GAAP measures to their closest U.S. GAAP equivalent are presented below. * Non-GAAP EBITDA is defined as net loss and comprehensive loss excluding amortization, depreciation, non-cash stock compensation, and taxes while reversing out the benefits derived from net interest income. ** Non-GAAP Adjusted EBITDA is defined as Non-GAAP EBITDA, as defined above, excluding impairment charges and non-recurring items; including but not limited to specialized accounting, tax, and audit services, new facility integration / start-up costs, and other one-time items. ZOMEDICA OF NON-GAAP FINANCIAL MEASURES(amounts in thousands)(unaudited) Three Months Ended March 31, 2025 2024 Net loss and comprehensive loss $ (63,765 ) $ (9,223 ) Amortization expense 1,692 1,597 Depreciation expense 521 334 Stock-compensation expense 618 1,101 Interest income (730 ) (1,093 ) Income tax benefit (57 ) (166 ) Non-GAAP EBITDA loss $ (61,721 ) $ (7,450 ) Impairment expense 55,833 - Proforma adjustments (1) 143 2,193 Adjusted Non-GAAP EBITDA loss $ (5,745 ) $ (5,257 ) (1) Proforma adjustments for the three months ended March 31, 2025 included $135 of one-time general and administrative expenses and $8 of one-time selling and marketing expenses. SOURCE: Zomedica Corp. View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
